Nonprofit · EIN 59-3097333
NATIONAL PEDIATRIC CANCER FOUNDATION INC
Tax-exempt · TAMPA, FL 33609
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| June 30, 2025 | 990 | $4,449,969 | $5,723,050 | -$1,273,081 | $6,202,847 | $1,059,559 | $5,143,288 |
| June 30, 2024 | 990 | $5,010,088 | $5,075,041 | -$64,953 | $7,031,609 | $930,873 | $6,100,736 |
Financial details: 990 for the year ended June 30, 2025
Revenue
- Contributions, gifts and grants
- $4,219,467
- Program service revenue
- $0
- Investment income
- $87,081
- Net gain from sales of assets
- -$42,296
- Net income from fundraising events
- $134,683
- Other revenue
- $143,421
Expenses
- Grants and similar amounts paid
- $3,441,620
- Compensation of officers, directors and key employees
- $492,986
- Other salaries and wages
- $1,023,485
- Salaries, compensation and benefits (total)
- $1,685,577
- Professional fundraising fees
- $0
- Occupancy
- $49,241
- Travel
- $17,857
- Depreciation
- $52,167
- Program services (functional)
- $5,120,886
- Management and general (functional)
- $246,144
- Fundraising (functional)
- $356,020
Balance sheet and other
- Total assets, start of year
- $7,031,609
- Total assets, end of year
- $6,202,847
- Total liabilities, end of year
- $1,059,559
- Net assets, end of year
- $5,143,288
- Land, buildings and equipment
- $1,514,645
- Publicly traded securities
- $3,050,583
- Net assets without donor restrictions
- $4,475,544
- Net assets with donor restrictions
- $667,744
- Gross receipts
- $7,238,881
- Employees
- 21
- Volunteers
- 300
- Year formed
- 1991
- State of legal domicile
- FL
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended June 30, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| DAVID FRAZER | CEO Officer | 40 | $210,377 |
| ROBERT MARTIN | CFO THRU OCTOBER 2024 Officer | 40 | $132,178 |
| DAWN ZACHMAN | COO Officer | 40 | $119,939 |
| JENNIFER FINNEMORE | CFO START OCTOBER 2024 Officer | 40 | $30,492 |
| ALBERT SILVA | CHAIRMAN OF THE BOARD Trustee or director, Officer | 2 | $0 |
| MICHAEL LEVIN | PAST CHAIR Trustee or director, Officer | 2 | $0 |
| RICHARD HUFF | VICE CHAIRMAN Trustee or director, Officer | 2 | $0 |
| ALEX SULLIVAN | VICE CHAIRMAN Trustee or director, Officer | 2 | $0 |
| JEREMY PERSINGER | TREASURER Trustee or director, Officer | 2 | $0 |
| JOHN FITZPATRICK | SECRETARY Trustee or director, Officer | 2 | $0 |
| MICHAEL WEIGNER | ASSISTANT SECRETARY Trustee or director, Officer | 2 | $0 |
| MELISSA DUNKEL | CO-FOUNDER AT LARGE Trustee or director | 1 | $0 |
| JIM BASSIL | DIRECTOR Trustee or director | 1 | $0 |
| BB ABBOTT | DIRECTOR Trustee or director | 1 | $0 |
| DAVID BOYINGTON | DIRECTOR Trustee or director | 1 | $0 |
11 more people on this return
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| CHRIS CARRERE | DIRECTOR AT LARGE Trustee or director | 1 | $0 |
| CARRIE CHARLES | DIRECTOR Trustee or director | 1 | $0 |
| CHAD HARROD | EMERITUS Trustee or director | 1 | $0 |
| JOSEPH LAMPHIER | DIRECTOR Trustee or director | 1 | $0 |
| JAY LANGFORD | DIRECTOR Trustee or director | 1 | $0 |
| JEFF MAXWELL | DIRECTOR AT LARGE Trustee or director | 1 | $0 |
| MARK MCHUGH | DIRECTOR AT LARGE Trustee or director | 1 | $0 |
| ANGELA NORTH | DIRECTOR Trustee or director | 1 | $0 |
| MARCO SCHNABL | DIRECTOR AT LARGE Trustee or director | 1 | $0 |
| DAWN SILER-NIXON | DIRECTOR Trustee or director | 1 | $0 |
| ASHLIE TEELING | DIRECTOR Trustee or director | 1 | $0 |
990 for the year ended June 30, 2024: 26 people
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| DAVID FRAZER | CEO Officer | 40 | $206,262 |
| ROBERT MARTIN | CFO Officer | 40 | $144,810 |
| DAWN ZACHMAN | COO Officer | 40 | $113,385 |
| MICHAEL LEVIN | CHAIRMAN OF THE BOARD Trustee or director, Officer | 2 | $0 |
| CHAD HARROD | VICE CHAIRMAN Trustee or director, Officer | 2 | $0 |
| ALBERT SILVA | VICE CHAIRMAN Trustee or director, Officer | 2 | $0 |
| JEREMY PERSINGER | TREASURER Trustee or director, Officer | 2 | $0 |
| JIM BASSIL | SECRETARY Trustee or director, Officer | 2 | $0 |
| MELISSA DUNKEL | AT LARGE DIRECTOR - EMERITUS Trustee or director | 1 | $0 |
| FRANK CAPITANO | AT LARGE DIRECTOR Trustee or director | 1 | $0 |
| JEFF MAXWELL | AT LARGE DIRECTOR Trustee or director | 1 | $0 |
| JOSEPH LAMPHIER | DIRECTOR - EMERITUS Trustee or director | 1 | $0 |
| MARCO SCHNABL | DIRECTOR Trustee or director | 1 | $0 |
| MARK MCHUGH | DIRECTOR Trustee or director | 1 | $0 |
| RICHARD HUFF | DIRECTOR Trustee or director | 1 | $0 |
| BB ABBOTT | DIRECTOR Trustee or director | 1 | $0 |
| CARRIE CHARLES | DIRECTOR Trustee or director | 1 | $0 |
| DAN DOYLE JR | DIRECTOR Trustee or director | 1 | $0 |
| JOHN FITZPATRICK | DIRECTOR Trustee or director | 1 | $0 |
| PHILIP MINARDI | DIRECTOR Trustee or director | 1 | $0 |
| ANGELA NORTH | DIRECTOR Trustee or director | 1 | $0 |
| DAWN SILER-NIXON | DIRECTOR Trustee or director | 1 | $0 |
| MIKE WEIGNER | DIRECTOR Trustee or director | 1 | $0 |
| ALEX SULLIVAN | DIRECTOR Trustee or director | 1 | $0 |
| CHRIS CARRERE | DIRECTOR Trustee or director | 1 | $0 |
| DAVID BOYINGTON | DIRECTOR Trustee or director | 1 | $0 |
Address and contacts
- Address (IRS master file)
- 5550 W EXECUTIVE DR STE 200, TAMPA, FL 33609-1046
- In care of
- % RISA R TRAMEL
- Principal officer (990 for 2024)
- DAVID FRAZER, 5550 WEST EXECUTIVE DRIVE SUITE 200, TAMPA, FL 33609
- Signed the 990
- DAVID FRAZER, CHIEF EXECUTIVE OFFICER
- Phone
- (813) 269-0955
- Website
- WWW.NATIONALPCF.ORG
- Return prepared by
- RIVERO GORDIMER & COMPANY PA
Mission
NATIONAL PEDIATRIC CANCER FOUNDATION (NPCF) IS A NONPROFIT ORGANIZATION DEDICATED TO FUNDING RESEARCH TO ELIMINATE CHILDHOOD CANCER. OUR FOCUS IS TO FUND RESEARCH TO FIND LESS TOXIC, MORE TARGETED THERAPIES BY PARTNERING WITH LEADING HOSPITALS NATIONWIDE.
Program accomplishments
- THE NATIONAL PEDIATRIC CANCER FOUNDATION FUNDS PEDIATRIC CANCER RESEARCH WITH THE GOAL OF LEADING TO THE TREATMENT AND ELIMINATION OF PEDIATRIC CANCER WORLDWIDE.WE ACCOMPLISH OUR MISSION THROUGH OUR RESEARCH INITIATIVE, THE SUNSHINE PROJECT, AN INNOVATIVE COLLABORATION OF 40 HOSPITALS NATIONWIDE. THIS COLLABORATIVE RESEARCH MODEL IS UNIQUE AND EFFECTIVE IN ACCELERATING THE DEVELOPMENT OF NEW TREATMENTS AGAINST CHILDHOOD CANCER.SEE SCHEDULE O FOR FURTHER PROGRAM SERVICE ACCOMPLISHMENTS.IN DEVELOPING THIS COLLABORATION, THE FOUNDATION HAS BROUGHT TOGETHER SOME OF THE COUNTRY'S LEADING INVESTIGATORS AND INSTITUTIONS TO DRIVE THE PROCESS OF FINDING A CURE. INVESTIGATORS ARE PERFORMING THREE VITAL PHASES OF RESEARCH SIMULTANEOUSLY: BASIC SCIENCE, TRANSLATIONAL RESEARCH AND CLINICAL TRIALS. THESE MAJOR RESEARCH COMPONENTS NOT ONLY ALLOW DOCTORS TO IDENTIFY NEW AGENTS IN FIGHTING CANCER, BUT ALSO HELP RESEARCHERS TO UNDERSTAND THE CANCER CELLS RESPONSE TO THE DRUG. THE NATIONAL PEDIATRIC CANCER FOUNDATION IS MAKING GREAT STRIDES IN ITS MISSION TO FIND A CURE FOR CHILDHOOD CANCER.CURRENT INITIATIVES OF THE SUNSHINE PROJECT ARE AS FOLLOWS:SARCOMA TRIALS (OSTEOSARCOMA, RHABDOMYOSARCOMA, EWING SARCOMA, NON-RHABDOMYOSARCOMA); BRAIN CANCER TRIALS (MEDULLOBLASTOMA, HIGH-GRADE GLIOMA); SOLID STATE TUMORS1. EVOLUTIONARY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA - METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA (RMS) HAVE A POOR OUTCOME WHICH IS WORSENED WITH ADDITIONAL RISK FACTORS COMMONLY CALLED THE OBERLIN CRITERIA. PATIENTS THAT MEET ALL 4 OBERLIN CRITERIA HAVE AN EVENT FREE SURVIVAL (EFS) OF LESS THAN 20% AT 2 YEARS. ALL THERAPEUTIC ARMS ON THIS STUDY ARE DESIGNED TO MEET THE SAME PRIMARY AIM OF IMPROVING THE 3-YEAR EVENT FREE SURVIVAL FROM 6% TO 35% FOR THESE PATIENTS. 2. BLOOD BASED BIOMARKERS FOR MINIMAL RESIDUAL DISEASE DETECTION IN PEDIATRIC SARCOMAS - THE PURPOSE OF THIS STUDY IS TO SEE IF DETECTING CELL-FREE PLASMA TUMOR DNA (PTDNA) AND CIRCULATING TUMOR CELLS (CTC) CAN PREDICT RECURRENCE OF DISEASE IN PATIENTS WHO ARE IN RADIOGRAPHIC REMISSION 2-3 WEEKS AFTER TREATMENT. PLASMA TUMOR DNA (PTDNA) IS FREE FLOATING DNA FROM THE TUMOR FOUND IN THE BLOOD STREAM AND CIRCULATING TUMOR CELLS.3. A MULTI-INSTITUTION STUDY OF TGFB IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NK CELL INFUSIONS AS ADOPTIVE IMMUNOTHERAPY IN COMBINATION WITH GEMCITABINE AND DOCETAXEL IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC BONE AND SOFT TISSUE SARCOMAS: THE TINKS TRIAL - THE PURPOSE OF THIS TRIAL IS TO DETERMINE THE SAFETY OF THE ADDITION OF ADOPTIVE TRANSFER OF UNIVERSAL DONOR, TGFB IMPRINTED (TGFBI), EXPANDED NK CELLS TO GEMCITABINE/DOCETAXEL (GEM/DOX) FOR TREATMENT OF RELAPSED AND REFRACTORY SARCOMAS AND TO DETERMINE THE 6 MONTH PROGRESSION FREE SURVIVAL ACHIEVED WITH THIS TREATMENT.4. FEASIBILITY OF GENERATING NOVEL TRANSLATIONAL AND THERAPEUTIC STRATEGIES BASED ON A MULTICENTER, PEDIATRIC AND AYA EVOLUTIONARY TUMOR BOARD (PEDSETB) - PEDIATRIC EVOLUTIONARY TUMOR BOARD (PEDSETB) IS A MULTIDISCIPLINARY FORUM TO APPROACH AN INDIVIDUAL PATIENT'S CANCER AND PROPOSE ADDITIONAL IDEAS FOR CARE. THE PEDSETB WILL GATHER DISCIPLINES NOT OFTEN ENGAGED IN CANCER WORK AND USE INSIGHTS FROM EVOLUTION TO OPTIMALLY MODEL, RESEARCH, AND IMPACT PEDIATRIC CANCER OUTCOMES. STRATEGIES FROM PEDSETB'S PREDECESSOR HAVE BEEN INSTRUMENTAL IN THE DESIGN OF SEVERAL OF NPCF'S MOST RECENT CLINICAL TRIALS5. EVALUATION OF DIGOXIN FOR RELAPSED NON-WNT, NON-SHH MEDULLOBLASTOMA (PHASE 2 STUDY) - THIS TRIAL WILL EVALUATE THE EFFICACY OF DIGOXIN IN TREATING PATIENTS WITH RELAPSED NON-SHH, NON-WNT MEDULLOBLASTOMA AND TO DETERMINE IF DIGOXIN IMPROVES PROGRESSION FREE SURVIVAL AT 4 MONTHS AFTER INITIATION OF STUDY TREATMENT IN THIS PATIENT POPULATION. 6. METASTATIC EWING'S TRIAL TESTING SCHEDULE ENHANCEMENT TO IMPROVE OUTCOMES - THIS TRIAL WILL TEST OUR ABILITY TO ADMINISTER FREQUENTLY CHANGING CHEMOTHERAPY REGIMENS, CALLED SEQUENTIAL SECOND STRIKES, TO PATIENTS WITH WIDELY METASTATIC EWING SARCOMA TO STOP ITS DEVELOPMENT OF RESISTANCE TO CHEMOTHERAPY AND IMPROVE CURE RATES.7. RNA LIPID PARTICLES TARGETING PEDIATRIC RECURRENT INTRACRANIAL MALIGNANCIES AND OTHER SYSTEMIC SOLID TUMORS - THIS TRIAL TESTS THE SAFETY, IMMUNE EFFECTS, AND POTENTIAL EFFECTIVENESS OF RNA-LOADED LIPID NANOPARTICLES (RNA-LP) VACCINES IN PATIENTS WITH RECURRENT PEDIATRIC HIGH-GRADE GLIOMA (PHGG), A TYPE OF BRAIN CANCER, AND RECURRENT OSTEOSARCOMA (OSA), A TYPE OF BONE CANCER. 8. OPEN-LABEL, COHORT-SEQUENTIAL DOSE-ESCALATION AND DOSE-CONFIRMATION PHASE 1-2 CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DOMATINOSTAT IN COMBINATION WITH SIROLIMUS IN ADOLESCENTS AND ADULTS WITH RELAPSED, REFRACTORY SARCOMA AND OSTEOSARCOMA - THIS TRIAL TESTS THE SAFETY AND EFFECTIVENESS OF TWO DRUGS, DOMATINOSTAT AND SIROLIMUS, USED TOGETHER IN PATIENTS WITH OSTEOSARCOMA AND OTHER SARCOMAS THAT HAVE COME BACK OR DON'T RESPOND TO OTHER TREATMENTS. 9. ENGINEERED DESTABILIZED AU RICH ELEMENTS OF C-MYC 3'UTR AS THERAPEUTICS FOR C-MYC DRIVEN PEDIATRIC CANCERS - THIS STUDY HAS IDENTIFIED A NOVEL TECHNOLOGY THAT CAN CONTROL AND DEGRADE A SPECIFIC C-MYC GENE (KNOWN AS THE MASTER REGULATOR) ACROSS MANY TYPES OF CANCERS. SINCE C-MYC IS DETECTED IN 74% OF HUMAN CANCERS, THE ABILITY TO DEGRADE AND ATTACK THIS COMMON LINK HAS THE POTENTIAL TO TRANSFORM THE TREATMENT OF CANCER. 10. TREATING LEPTOMENINGEAL SPREAD OF PEDIATRIC MEDULLOBLASTOMA WITH QUANTUM RADIOLOGY - THIS STUDY WILL USE QUANTUM MECHANICS TO PRECISELY TARGET SPECIFIC TUMOR CELLS WITHOUT HARMING NORMAL CELLS. THE METHOD USES CONVENTIONAL CLINICAL PROCEDURES IN A NOVEL COMBINATION WITHIN A WEAK MAGNETIC FIELD, AKIN TO A REFRIGERATOR MAGNET'S, SUCH THAT IF SUCCESSFUL IT COULD BE INTRODUCED INTO ANY HOSPITAL WITHOUT MAJOR INFRASTRUCTURAL, FINANCIAL OR PROCEDURAL DIFFICULT TO TREAT CHILDREN AND EVEN INFANTS WITH MEDULLOBLASTOMA, THE MOST COMMON CHILDHOOD BRAIN CANCER.Expenses $5,120,886 · grants $3,441,620
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in June, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | June 30, 2026 | November 16, 2026 | Not due yet |
| 2024 | June 30, 2025 | November 17, 2025 | 990 on file |
| 2023 | June 30, 2024 | November 15, 2024 | 990 on file |
IRS record
- EIN
- 59-3097333
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (509(a)(2))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 1992
- Accounting year ends
- June
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Health care (E30Z)
- Assets (IRS master file)
- $6,202,847
- Income (IRS master file)
- $7,238,881
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | June 2025 | $4,449,969 | $5,723,050 | $6,202,847 | XML |
| 990 | June 2024 | $5,010,088 | $5,075,041 | $7,031,609 | XML |
| 990 | June 2023 | $4,849,523 | $4,951,075 | $6,837,500 | IRS |
| 990 | June 2022 | $4,349,128 | $4,273,754 | $5,857,840 | IRS |
| 990 | June 2021 | – | – | – | IRS |
| 990 | June 2019 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 59-3097333).
Questions about NATIONAL PEDIATRIC CANCER FOUNDATION INC
- What is the EIN of NATIONAL PEDIATRIC CANCER FOUNDATION INC?
- The employer identification number (EIN) of NATIONAL PEDIATRIC CANCER FOUNDATION INC is 59-3097333.
- Is NATIONAL PEDIATRIC CANCER FOUNDATION INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1992.
- Are donations to NATIONAL PEDIATRIC CANCER FOUNDATION INC tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does NATIONAL PEDIATRIC CANCER FOUNDATION INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of NATIONAL PEDIATRIC CANCER FOUNDATION INC due?
- The return for tax year 2025 (the year ending June 30, 2026) is due November 16, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did NATIONAL PEDIATRIC CANCER FOUNDATION INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended June 2025.
- Who is the principal officer of NATIONAL PEDIATRIC CANCER FOUNDATION INC?
- The 990 for the year ended June 30, 2025 names DAVID FRAZER.
- Who are the officers and directors of NATIONAL PEDIATRIC CANCER FOUNDATION INC?
- The 990 for the year ended June 30, 2025 lists 26 people; 4 received compensation from the organization, the highest $210,377 (DAVID FRAZER, CEO).
- How much revenue does NATIONAL PEDIATRIC CANCER FOUNDATION INC have?
- On its 990 for the year ended June 30, 2025 it reported revenue of $4,449,969, expenses of $5,723,050 and total assets of $6,202,847 at year end.
Other nonprofits in TAMPA
- FLORIDA HEALTH SCIENCES CENTER INC EIN 59-3458145 · last filed 990 for 2025
- H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC EIN 59-3238634 · last filed 990 for 2025
- SHRINERS HOSPITALS FOR CHILDREN EIN 36-2193608 · last filed 990 for 2025
- UNIVERSITY COMMUNITY HOSPITAL INC EIN 59-1113901 · last filed 990 for 2024
- BAYCARE MEDICAL GROUP INC EIN 59-3140335 · last filed 990 for 2024
- LIFELINK FOUNDATION INC EIN 59-2193032 · last filed 990 for 2025
- TAMPA GENERAL PROVIDER NETWORK INC EIN 86-1810505 · last filed 990 for 2025
- TAMPA FAMILY HEALTH CENTERS INC EIN 59-2420282 · last filed 990 for 2025